Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 6/20 | 0.69 |
| ▸ | GPBAR1 | Q8TDU6 | 5/20 | 0.69 |
| ▸ | CASP7 | P55210 | 3/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.69 |
| ▸ | TP53 | P04637 | 2/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.69 |
| ▸ | BLM | P54132 | 2/20 | 0.69 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.69 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.69 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.69 |
| ▸ | USP2 | O75604 | 2/20 | 0.69 |
| ▸ | MDM4 | O15151 | 1/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.69 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.69 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15156945 | 1.00 | VDR (0.69) | VDRGPBAR1CASP7HSD17B10TDP1 | |
| SCHEMBL5154446 | 1.00 | VDR (0.69) | VDRGPBAR1CASP7HSD17B10TDP1 | |
| SCHEMBL22572509 | 0.95 | GPBAR1 (0.62) | VDRGPBAR1CASP7HSD17B10TDP1 | |
| SCHEMBL6064363 | 0.94 | GPBAR1 (0.61) | VDRGPBAR1CASP7HSD17B10TDP1 | |
| SCHEMBL4331335 | 0.90 | GPBAR1 (0.73) | VDRGPBAR1CASP7HSD17B10TDP1 | |
| SCHEMBL6064374 | 0.88 | GPBAR1 (0.56) | VDRGPBAR1CASP7HSD17B10TDP1 | |
| SCHEMBL22495528 | 0.88 | GPBAR1 (0.56) | VDRGPBAR1CASP7HSD17B10TDP1 | |
| SCHEMBL16906787 | 0.87 | OSBP (0.53) | VDRGPBAR1CASP7HSD17B10TDP1 | |
| SCHEMBL2155391 | 0.86 | CYP2D6 (0.63) | TP53LMNAUSP2MEN1KMT2A | |
| SCHEMBL16227067 | 0.86 | CYP2D6 (0.63) | TP53LMNAUSP2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3423829-A1 | METHOD FOR DETERMININGIN VITRO | Clayton Pharmaceuticals LLC (US) | 2019-01-09 | — | — | EP | claimed |
| WO-2018204894-A1 | METHOD FOR DETERMINING IN VITRO BIOEQUIVALENCE OF A SUCRALFATE SUSPENSION SAMPLE TO A SUCRALFATE SUSPENSION REFERENCE LISTED DRUG (RLD) | CLAYTON PHARMACEUTICALS LLC (US) | 2018-11-08 | — | — | WO | claimed |
| US-9989519-B1 | Method for determining in vitro bioequivalence of a sucralfate suspension sample to a sucralfate suspension reference listed drug (RLD) | Clayton Pharmaceuticals, LLC (US) | 2018-06-05 | — | — | US | claimed |
| US-12023346-B1 | Compositions and methods for treating epilepsy | POVIVA CORP (US) | 2024-07-02 | — | — | US | disclosed |
| EP-2470553-B1 | POLYHYDROXYLATED BILE ACIDS FOR TREATMENT OF BILIARY DISORDERS | QING BILE THERAPEUTICS INC (CA) | 2024-06-19 | — | — | EP | disclosed |
| EP-4133266-A1 | IMPROVED METHODS FOR EVALUATING LIVER FUNCTION | Hepquant, LLC (US) | 2023-02-15 | — | — | EP | disclosed |
| US-20210318274-A1 | METHODS FOR EVALUATING LIVER FUNCTION | HepQuant, LLC | 2021-10-14 | — | — | US | disclosed |
| US-11066437-B2 | Methods and intermediates for the preparation of bile acid derivatives | INTERCEPT PHARMACEUTICALS, INC. (US) | 2021-07-20 | — | — | US | disclosed |
| EP-3426348-B1 | 3-DESOXY DERIVATIVE AND PHARMACEUTICAL COMPOSITIONS THEREOF | INTERCEPT PHARMACEUTICALS INC (US) | 2021-05-05 | — | — | EP | disclosed |
| EP-3645548-A1 | METHODS FOR PREPARING BILE ACIDS | Medytox Inc. (KR) | 2020-05-06 | — | — | EP | disclosed |
| US-10604544-B2 | Methods for preparation of bile acids and derivatives thereof | INTERCEPT PHARMACEUTICALS, INC. (US) | 2020-03-31 | — | — | US | disclosed |
| EP-1012331-A4 | COMPOSITIONS AND METHODS FOR THE DELIVERY OF OLIGONUCLEOTIDES VIA THE ALIMENTARY CANAL | ISIS PHARMACEUTICALS INC (US) | 2002-06-26 | — | — | EP | disclosed |
| EP-1080103-A1 | COMPOSITIONS AND METHODS FOR NON-PARENTERAL DELIVERY OF OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 2001-03-07 | — | — | EP | disclosed |
| EP-1012331-A1 | COMPOSITIONS AND METHODS FOR THE DELIVERY OF OLIGONUCLEOTIDES VIA THE ALIMENTARY CANAL | ISIS PHARMACEUTICALS, INC. (US) | 2000-06-28 | — | — | EP | disclosed |
| WO-1999060012-A1 | COMPOSITIONS AND METHODS FOR NON-PARENTERAL DELIVERY OF OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 1999-11-25 | — | — | WO | disclosed |
| WO-1999001579-A1 | COMPOSITIONS AND METHODS FOR THE DELIVERY OF OLIGONUCLEOTIDES VIA THE ALIMENTARY CANAL | ISIS PHARMACEUTICALS, INC. (US) | 1999-01-14 | — | — | WO | disclosed |
| US-5795870-A | STEROID RING WITH AMINE GROUP SIDE CHAINS | TRUSTEES OF PRINCETON UNIVERSITY (US) | 1998-08-18 | — | — | US | disclosed |
| EP-0168229-B1 | PHARMACEUTICAL ANTIFUNGAL COMPOSITION | BTG INTERNATIONAL LIMITED (GB) | 1993-09-15 | — | — | EP | disclosed |
| US-4681876-A | Antifungal utility of bile acids | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1987-07-21 | — | — | US | disclosed |
| EP-0168229-A2 | Pharmaceutical antifungal composition | BTG INTERNATIONAL LIMITED (GB) | 1986-01-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10604544-B2 | Methods for preparation of bile acids and derivatives thereof | SLC10A2, SLC10A1, NR1H4 | VDR 1221/4885GPBAR1 7/4885CASP7 1683/4885 |
| US-11066437-B2 | Methods and intermediates for the preparation of bile acid derivatives | SLC10A1, SLC10A2, NR1H4 | VDR 2312/4885GPBAR1 8/4885CASP7 1129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.